Matthew Judson is a research associate in the UNC Neuroscience Center at the University of North Carolina at Chapel Hill.
Matthew Judson
Research associate
University of North Carolina at Chapel Hill
From this contributor
Angelman syndrome: Bellwether for genetic therapy in autism
It is not a matter of whether there will be clinical trials of genetic therapy for Angelman syndrome, but when.
Angelman syndrome: Bellwether for genetic therapy in autism
Insights for autism from Angelman syndrome
Deletions or duplications of the UBE3A gene lead to both Angelman syndrome and some cases of autism, respectively. Studying the effects of altered gene dosage in this region will provide insights into brain defects and suggest targets for therapies for both disorders, says expert Benjamin Philpot.
Insights for autism from Angelman syndrome
Explore more from The Transmitter
Sylvia Fogel, reshaping U.S. autism research strategy
In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.
Sylvia Fogel, reshaping U.S. autism research strategy
In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.
Human brain organoids flourish in emptied mouse cortex
The chimeric mice could help untangle the biology of human brain development or conditions such as autism.
Human brain organoids flourish in emptied mouse cortex
The chimeric mice could help untangle the biology of human brain development or conditions such as autism.
What if Hegel were a neuroscientist?
Andrea Gambarotto shares what Hegel and enactivism have in common: an agency-first approach to understanding minds and brains.
What if Hegel were a neuroscientist?
Andrea Gambarotto shares what Hegel and enactivism have in common: an agency-first approach to understanding minds and brains.